Lab Work for GLP-1 Weight Loss Patients: What We Check and Why

Starting a GLP-1 medication like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) isn't as simple as getting a prescription and stepping on a scale every week. These are powerful medications that affect your metabolism, blood sugar, thyroid, liver, kidneys, and nutritional status. Responsible prescribing means knowing where you start, monitoring how your body responds, and catching potential issues before they become problems.

Here's what lab work Dr. Kim orders for weight loss patients at Coral, what each test tells us, and why it matters for your safety and results.

Baseline Labs: Before Starting Treatment

Before writing a GLP-1 prescription, we need a clear picture of your metabolic health. This isn't optional — it's the foundation for safe treatment.

Hemoglobin A1C

Why we check it: A1C tells us your average blood sugar over the past 2-3 months. It determines whether you're in the normal, prediabetic, or diabetic range and directly influences medication choice and dosing.

What we're looking for: Patients with A1C in the prediabetic range (5.7-6.4%) benefit from GLP-1 medications on two fronts — weight loss and improved glycemic control. Patients with diabetes (A1C 6.5%+) may need different dosing considerations and closer glucose monitoring. Patients with normal A1C are still appropriate candidates, but blood sugar response may differ.

Why it matters during treatment: GLP-1 medications lower blood sugar. We need to know your starting point to ensure we're improving metabolic health without overcorrecting — particularly if you're also on other diabetes medications.

Comprehensive Metabolic Panel (CMP)

Why we check it: The CMP covers 14 values in one draw — glucose, kidney function (BUN, creatinine, GFR), liver function (ALT, AST, ALP, bilirubin), electrolytes (sodium, potassium, chloride, CO2), calcium, albumin, and total protein.

What we're looking for:

• Kidney function: GLP-1 medications are generally safe for the kidneys (and may even be protective), but we need baseline kidney function to monitor for any changes, especially in patients with dehydration risk from reduced appetite and fluid intake.
• Liver function: Baseline liver enzymes ensure we can distinguish medication-related changes from pre-existing liver conditions. Non-alcoholic fatty liver disease (NAFLD) is extremely common in patients seeking weight loss treatment, and we expect liver enzymes to improve with weight loss.
• Glucose: Fasting glucose provides a point-in-time comparison to the A1C trend.
• Electrolytes: GLP-1 medications can cause nausea, vomiting, and diarrhea — particularly during dose escalation. These side effects can disrupt electrolyte balance if severe. Having a baseline means we know what to compare against.

Lipid Panel

Why we check it: Cholesterol and triglyceride levels are part of the metabolic picture and a major indicator of cardiovascular risk.

What we're looking for: Total cholesterol, LDL, HDL, and triglycerides. Many weight loss patients have dyslipidemia (abnormal lipid levels) at baseline. One of the most rewarding aspects of GLP-1 treatment is watching these values improve — particularly triglycerides, which often drop significantly with weight loss.

Why it matters: Tracking lipid improvements gives us objective evidence that your treatment is reducing cardiovascular risk, not just the number on the scale.

Thyroid Panel (TSH at minimum, often free T4)

Why we check it: This is both a safety screen and a diagnostic step.

Safety concern: GLP-1 receptor agonists carry an FDA black box warning about medullary thyroid carcinoma (MTC) — a rare type of thyroid cancer. This warning is based on animal studies (rodents developed thyroid tumors at very high doses). It has not been observed in humans, but out of caution, GLP-1 medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Diagnostic step: Undiagnosed hypothyroidism is a common contributor to weight gain and difficulty losing weight. If your thyroid is underactive and we don't catch it, you'll struggle with weight loss even on a GLP-1 — and we'll be treating the symptom without addressing a root cause.

Complete Blood Count (CBC)

Why we check it: A CBC establishes baseline red blood cells, white blood cells, and platelets. While GLP-1 medications don't directly affect blood counts, rapid weight loss and dietary changes can unmask nutritional deficiencies (iron, B12, folate) that show up on the CBC.

What we're watching for: Signs of anemia, nutritional deficiency, or other undiagnosed conditions that might be contributing to fatigue or other symptoms attributed to weight.

Additional Baseline Tests (Case-Dependent)

Depending on your history and presentation, Dr. Kim may also order:

• Fasting insulin: To assess insulin resistance directly
• Vitamin D: Deficiency is common in overweight patients and affects metabolism, mood, and energy
• Iron studies and ferritin: Particularly in women with fatigue and heavy periods
• Testosterone (in men): Obesity suppresses testosterone, and weight loss often restores it

Monitoring Labs: During Treatment

Once you're on a GLP-1 medication, monitoring continues on a regular schedule. This isn't just about safety — it's about optimizing your results and catching improvements you might not notice on your own.

3-Month Check

What we recheck: CMP (kidney and liver function), A1C, and fasting glucose

Why: The first three months are when most dose escalation happens and when side effects (nausea, reduced appetite, GI changes) are most likely. We want to make sure your kidneys and liver are handling the medication well, and we want to see your first A1C on treatment.

What we're hoping to see: Improved fasting glucose, dropping A1C (particularly in prediabetic patients), stable kidney and liver function.

Red flags we watch for: Rising creatinine (could indicate dehydration from reduced fluid intake or GI side effects), significantly worsening liver enzymes, or electrolyte imbalances.

6-Month Check

What we recheck: CMP, A1C, lipid panel, CBC

Why: By six months, most patients are on their target dose and seeing significant weight loss. This is when metabolic improvements become most visible in lab work.

What we're hoping to see: A1C moving toward normal range, improving lipid panel (especially triglycerides and LDL), stable or improving liver enzymes (fatty liver often improves with weight loss), normal kidney function, and no signs of nutritional deficiency on CBC.

12-Month Check and Beyond

What we recheck: Full panel — CMP, A1C, lipid panel, CBC, thyroid, and any additional markers from baseline

Why: Annual comprehensive labs track long-term metabolic health improvements and catch any emerging issues. Weight loss is not just about the number on the scale — it's about measurable improvements in the biological markers that drive chronic disease.

What Dr. Kim looks for at the one-year mark:

• A1C below 5.7% (if it was elevated at baseline)
• Improved lipid panel across all values
• Normal liver enzymes (or improving trend)
• Stable kidney function
• Normal thyroid function
• No nutritional deficiencies developing from reduced food intake
• Whether medication can be dose-reduced or, in some cases, discontinued with maintained lifestyle changes

Nutritional Monitoring: The Overlooked Piece

GLP-1 medications significantly reduce appetite. While this is the mechanism that drives weight loss, it also means patients eat less — sometimes dramatically less. Eating less means consuming fewer nutrients, and over months, this can create deficiencies.

Nutrients we watch for:

• Protein: Inadequate protein intake during weight loss leads to muscle loss, which undermines metabolic health. We counsel patients to prioritize protein even when appetite is reduced.
• Iron: Reduced food intake combined with menstrual losses can accelerate iron depletion in women.
• Vitamin B12: Patients with reduced gastric emptying (a GLP-1 effect) may absorb B12 less efficiently.
• Vitamin D: Already commonly deficient; reduced dietary intake can worsen it.

This is why lab monitoring on GLP-1 medications goes beyond just checking a box — it's about making sure you're losing fat safely while preserving muscle and nutritional health.

Why This Matters

The difference between responsible GLP-1 prescribing and irresponsible prescribing is monitoring. Anyone can write a prescription. But tracking your metabolic markers, catching problems early, adjusting doses based on real data, and documenting measurable improvements in your health — that's medicine.

At Coral, your weight loss treatment is built on lab data from day one. We track your progress with objective numbers, not just the scale. We explain every result. And we adjust your treatment based on what your body is telling us.

Ready to start your weight loss journey with the lab work to back it up? Start your visit with Coral.

[Start your visit — Weight Loss](/intake/weight-loss)